- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03364153
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
September 7, 2022 updated by: IVERIC bio, Inc.
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sonia Cruz
- Phone Number: 347-322-8722
- Email: [email protected]
Study Locations
-
Canada
-
-
Montréal, Canada, H4A 3J1
- Withdrawn
- Montreal Children's Hospital
-
-
-
France
-
-
Créteil, France, 94000
- Completed
- Hopital Intercommunal de Verdun, University Paris Est
-
Paris, France, 75012
- Completed
- Centre ophtalmologique des Quinzes Vingts
-
-
Rhone-Alpes
-
Lyon, Rhone-Alpes, France, 69317
- Completed
- Hopital de la Croix-Rousse
-
-
-
Germany
-
-
Bonn, Germany, 53127
- Completed
- University of Bonn
-
München, Germany, 80336
- Completed
- Augenklinik und Poliklinik des Klinikums der Universitat München
-
Tübingen, Germany, 72076
- Completed
- Universitätsklinikum Tübingen
-
-
-
Hungary
-
-
Budapest, Hungary, 1133
- Completed
- Budapest Retina Associates
-
Budapest, Hungary, H-1085
- Completed
- Semmelweis University, Ophthalmology Clinics
-
Debrecen, Hungary, 4032
- Completed
- Debreceni Egyetem Klinikai Kozpont Szemklinika
-
Pécs, Hungary, 7621
- Completed
- Ganglion Medical Center
-
Szeged, Hungary, 6720
- Completed
- Szegedi Tudomanyegyetem, Szent-Gyorgyi Albert Klinikai Kozpont, Szemeszeti Klinika
-
-
-
Israel
-
-
Haifa, Israel, 310960
- Completed
- Rambam Health Care Campus
-
Jerusalem, Israel, 91120
- Completed
- Hadassah Medical Center
-
Petah tikva, Israel, 4941492
- Completed
- Rabin Medical Center, Beilinson Campus
-
Reẖovot, Israel, 7610001
- Completed
- Kaplan Medical Center
-
Tel Aviv, Israel, 64239
- Completed
- Tel-Aviv Sourasky Medical Center, Ichilov Hospital
-
-
-
Italy
-
-
Bologna, Italy, 40138
- Completed
- AOU Policlinico Sant'Orsola Malpighi, U.O. Oftalmologia,
-
Florence, Italy, 50134
- Completed
- AOU Careggi
-
Milano, Italy, 20132
- Completed
- IRCCS Ospedale San Raffaele
-
Naples, Italy, 80131
- Completed
- AOU Universita degli studi della Campania Luigi Vanvitelli - UOC Oculistica
-
Rome, Italy, 00133
- Completed
- Foundation Policlinico Tor Vergata, UOSD Patologie Retiniche
-
-
-
Spain
-
-
Barcelona, Spain, 08022
- Completed
- Institut de la Màcula
-
-
-
United Kingdom
-
-
Edinburgh, United Kingdom, EH3 9HA
- Completed
- Princess Alexandra Eye Pavillion
-
London, United Kingdom, EC1V 2PD
- Completed
- Moorfields Eye Hospital
-
-
-
United States
-
Arizona
-
Phoenix, Arizona, United States, 85053
- Recruiting
- Retinal Consultants of Arizona
-
Contact:
- Phone Number: 602-222-2221
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- Jules Stein Eye Institute/ David Geffen School of Medicine
-
Contact:
- Phone Number: 310-267-5278
-
-
Florida
-
Gainesville, Florida, United States, 32607
- Recruiting
- VitreoRetinal Associates
-
Contact:
- Phone Number: 352-300-8412
-
Pensacola, Florida, United States, 32503
- Recruiting
- Retinal Specialty Institute
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Completed
- Wilmer Eye Institute, Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Completed
- Ophthalmic Consultants of Boston
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- Recruiting
- Kellogg Eye Center
-
Contact:
- Phone Number: 734-936-9798
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Recruiting
- Retina Center P.A.
-
Contact:
- Phone Number: 612-747-5644
-
-
New Jersey
-
Bloomfield, New Jersey, United States, 07003
- Recruiting
- Envision Ocular, LLC
-
Contact:
- Phone Number: 973-707-5632
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health & Science University
-
Contact:
- Phone Number: 503-494-3115
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Mid Atlantic Retina
-
Contact:
- Phone Number: 215-928-3092
-
Pittsburgh, Pennsylvania, United States, 15213
- Completed
- UPMC Eye Center
-
-
South Carolina
-
West Columbia, South Carolina, United States, 29169
- Recruiting
- Palmetto Retina Center
-
Contact:
- Phone Number: 803-404-5038
-
-
Texas
-
Austin, Texas, United States, 78705
- Recruiting
- Austin Retina Associates
-
Contact:
- Phone Number: 512-451-0103
-
Dallas, Texas, United States, 75231
- Recruiting
- Retina Foundation of the Southwest
-
Contact:
- Phone Number: 214-363-3911
-
Willow Park, Texas, United States, 76087
- Recruiting
- Strategic Clinical Research Group
-
Contact:
- Phone Number: 682-703-4324
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Recruiting
- University of Utah John A. Moran Eye Center
-
Contact:
- Phone Number: 801-581-6265
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least two pathogenic mutations of ABCA4 gene confirmed by a CLIA-certified laboratory
- Best corrected visual acuity in the study eye between 20/20 - 20/200 Snellen equivalent, inclusive
Exclusion Criteria:
- Macular atrophy secondary to any condition other than STGD1 in either eye
- Any prior treatment for STGD1 including gene therapy, stem cell therapy or any prior intravitreal treatment for any indication in either eye
- Participation in an interventional study of a vitamin A derivative ≤ 3 months prior to screening
- Presence of intraocular inflammation, macular hole, pathologic myopia, epiretinal membrane, evidence of significant vitreo-macular traction, vitreous hemorrhage or aphakia
- Any intraocular surgery or thermal laser within 3 months of trial entry. Any prior thermal laser in the macular region
- Diabetes mellitus
- HbA1c value of ≥6.5%
- Stroke within 12 months of trial entry
- Any major surgical procedure within one month of trial entry or anticipated during the trial
- Any treatment with an investigational agent in the past 60 days for any condition
- Women who are pregnant or nursing
- Known serious allergies to the fluorescein dye used in angiography, povidone iodine, or to the components of the Zimura formulation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Zimura dose group
|
Zimura Intravitreal Injection
Other Names:
|
Sham Comparator: Cohort 2
Sham dose group
|
Sham Intravitreal Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spectral Domain-Optical Coherence Tomography (SD-OCT)
Time Frame: 18 months
|
Mean rate of change in the area of ellipsoid zone defect measured by en face SD-OCT
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 12, 2018
Primary Completion (Anticipated)
September 1, 2024
Study Completion (Anticipated)
September 1, 2024
Study Registration Dates
First Submitted
December 1, 2017
First Submitted That Met QC Criteria
December 1, 2017
First Posted (Actual)
December 6, 2017
Study Record Updates
Last Update Posted (Actual)
September 9, 2022
Last Update Submitted That Met QC Criteria
September 7, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPH2005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stargardt Disease 1
-
NCT05674058RecruitingConditions: Stargardt Disease, Stargardt Disease 1, Fundus Flavimaculatus, Macular Degeneration, Stargardt, Macular Dystrophy With Flecks, Type 1
-
NCT05244304Recruiting
-
NCT03364153RecruitingConditions: Stargardt Disease 1
-
NCT05258032RecruitingConditions: Retinitis Pigmentosa, Stargardt Disease 1, Best Disease, Pattern Dystrophy of Macula, Choroideremia
-
NCT02402660RecruitingConditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
-
NCT04239625Enrolling by invitationConditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
-
NCT04489511CompletedConditions: Stargardt Disease-1
-
NCT03297515CompletedConditions: Dry AMD, Stargardt Disease 1
-
NCT04281732RecruitingConditions: Low Vision, Retinitis Pigmentosa, Stargardt Disease 1, Stargardt Disease 3, Stargardt Disease 4, Albinism
-
NCT03772938Unknown statusConditions: Retinal Degeneration, Retinitis Pigmentosa, Age Related Macular Degeneration, Stargardt Disease 1
Clinical Trials on Zimura
-
NCT05571267CompletedConditions: Macular Degeneration
-
NCT04435366Active, not recruitingConditions: Geographic Atrophy, Macular Degeneration
-
NCT03364153RecruitingConditions: Stargardt Disease 1
-
NCT02686658CompletedConditions: Geographic Atrophy, Macular Degeneration
-
NCT03362190CompletedConditions: Wet Age-related Macular Degeneration
-
NCT02397954CompletedConditions: Idiopathic Polypoidal Choroidal Vasculopathy
-
NCT03374670WithdrawnConditions: Idiopathic Polypoidal Choroidal Vasculopathy